Urticaria treatment options
Pro Research Analysisby 
Searched over 200M research papers
First-Line Urticaria Treatment: Second-Generation Antihistamines
The primary treatment for urticaria, especially chronic urticaria, is the use of second-generation, non-sedating H1-antihistamines. These medications are preferred due to their safety and effectiveness. If symptoms persist, the dosage can be increased up to four times the standard dose, as recommended by current guidelines 1246+3 MORE.
Second-Line and Add-On Therapies: Omalizumab and Cyclosporine
For patients who do not respond to high-dose antihistamines, omalizumab, a monoclonal anti-IgE antibody, is the next recommended step. Omalizumab is effective in a significant proportion of antihistamine-refractory cases and is considered a major advancement in urticaria management 3467+2 MORE. If omalizumab is not effective, cyclosporine, an immunosuppressive agent, may be used, though it requires careful monitoring due to potential side effects 2456+2 MORE.
Additional and Alternative Treatments for Refractory Urticaria
For patients who remain unresponsive to antihistamines, omalizumab, and cyclosporine, several other options are available, though evidence for their routine use is limited. These include:
- Leukotriene receptor antagonists (e.g., montelukast)
- Anti-inflammatory drugs (e.g., dapsone, sulfasalazine, hydroxychloroquine)
- Other immunosuppressive drugs (e.g., methotrexate, azathioprine, mycophenolate mofetil)
- Intravenous immunoglobulin (IVIG)
- Short-term systemic corticosteroids for acute exacerbations (not recommended for long-term use due to toxicity)
- Phototherapy (UVA, UVB) 1256+1 MORE
These treatments are generally reserved for specific cases where standard therapies have failed, and their use should be individualized and closely monitored 1569.
Emerging and Future Urticaria Treatments
Research is ongoing into new therapies targeting the underlying mechanisms of urticaria. Promising options in clinical trials and development include:
- Bruton’s tyrosine kinase (BTK) inhibitors (e.g., remibrutinib, fenebrutinib)
- New anti-IgE monoclonal antibodies (e.g., ligelizumab, UB-221)
- Biologics targeting interleukin pathways (e.g., dupilumab, reslizumab, mepolizumab, benralizumab)
- Agents targeting mast cell receptors and other immune pathways (e.g., MRGPRX2 inhibitors, Siglec-8 antibodies, tyrosine kinase receptor Kit inhibitors like barzolvolimab)
- Other novel targets such as the histamine 4 receptor, C5a and its receptor, and cytokines like IL-33, IL-25, and thymic stromal lymphopoietin 347.
These emerging therapies offer hope for patients with difficult-to-treat urticaria and may lead to more personalized and effective management strategies in the future 347.
Special Considerations and Combination Therapies
In patients with comorbidities or those requiring multiple therapies, combining antihistamines with other agents such as omalizumab, cyclosporine, montelukast, or dapsone has been shown to be feasible and generally safe . Treatment approaches may also need to be adjusted for special populations, such as children or pregnant women .
Conclusion
Urticaria treatment typically begins with second-generation antihistamines, escalating to higher doses if needed. Omalizumab and cyclosporine are key options for refractory cases, while other immunosuppressive and anti-inflammatory agents may be considered when standard therapies fail. New biologics and targeted therapies are under investigation and may soon expand the range of effective treatments, offering hope for more personalized and long-term disease control 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
New treatments for chronic urticaria.
New treatments for chronic urticaria, including off-label use of existing drugs and novel therapies in clinical trials, show promise in improving patient outcomes.
DOI